Citations

Clear

6274 citation(s) found for "To, Andrew".

BRAF Rearrangements and BRAF V600E Mutations Are Seen in a Subset of Pancreatic Carcinomas With Acinar Differentiation
Ghosh, Toshi, Greipp, Patricia T. , Knutson, Darlene L., Kloft‐Nelson, Sara M. , Jenkins, Sarah M. , Mounajjed, Taofic, Said, Samar M. , Sessa, Fausto , Naini, Bita V. , Zhang, Lizhi , Kerr, Sarah E. , Graham, Rondell P. , Knutson, Darlene, Kloft-Nelson, Sara, Graham, Rondell P , Greipp, Patricia T , Rosa, Stefano La , Vanoli, Alessandro , Bellizzi, Andrew M.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | October 9, 2021 | Volume: 146 | Issue: 7 | Pages: 840-845

10.5858/arpa.2020-0739-oa | PMID 34614142 Get It

Context.— Comprehensive genomic profiling has demonstrated that approximately 20% of pancreatic carcinomas with acinar differentiation harbor potentially targetable BRAF fusions that activate the MAPK pathway. Objectives.— To validate the above finding by BRAF break-apart fluorescence in situ hybridization (FISH) in a large series of pure acinar cell carcinomas (ACCs), evaluate tumors for the presence of BRAF V600E mutations, and compare clinicopathologic features of tumors with BRAF rearrangements with those without. Design.— Thirty cases of pure ACC and 6 cases of mixed acinar-neuroendocrine carcinoma (ACC-NEC) were retrieved. A break-apart FISH probe was used to detect BRAF rearrangements. Immunohistochemistry for BRAF V600E was performed. Results.— BRAF rearrangements by FISH were found in 6 of 36 cases (17%), 5 of which were pure ACC and 1 was a mixed ACC-NEC. Follow-up was available in 29 of 36 cases (81%). The median survival was 22 months for BRAF-rearranged cases and 16 months for BRAF-intact cases; the 2-year overall survival was 50% for BRAF-rearranged cases and 35% for BRAF-intact cases. No significant clinicopathologic differences were identified in cases with BRAF rearrangement compared with those without BRAF rearrangement. BRAF V600E mutation was identified in 2 of 34 cases (6%), both of which were pure ACC and were BRAF-intact by FISH. Conclusions.— This study supports the finding that BRAF rearrangements are present in approximately 20% of cases and identified BRAF V600E mutations in approximately 5% of cases. These cases may benefit from targeted therapy.
Mendelian Randomisation Study of Smoking, Alcohol, and Coffee Drinking in Relation to Parkinson’s Disease
Domenighetti, Cloé , Sreelatha, Ashwin Ashok Kumar , Grover, Sandeep , Mohamed, Océane, Portugal, Berta , May, Patrick , Bobbili, Dheeraj Reddy , Radivojkov‐Blagojevic, Milena , Lichtner, Peter , Singleton, Andrew , Hernandez, Dena G., Edsall, Connor , Mellick, George D. , Zimprich, Alexander , Pirker, Walter , Kõks, Sulev, Lesage, Suzanne , Chartier‐Harlin, Marie‐Christine , Brockmann, Kathrin , Deutschländer, Angela , Hadjigeorgiou, G., Dardiotis, Efthimos, Simitsi, Athina Maria, Petrucci, Simona , Straniero, Letizia , Pezzoli, Gianni , Brighina, Laura , Ferrarese, Carlo , Annesi, Grazia , Quattrone, Andrea , Kawamura, Yusuke , Hattori, Nobutaka , Kim, Yun Joong , Kolber, Pierre, Warrenburg, Bart P. van de, Bloem, Bastiaan R. , Aasly, Jan , Toft, Mathias , Ferreira, Joaquim J. , Bardien, Soraya , Tolosa, Eduardo , Ezquerra, Mario , Pástor, Pau , Wirdefeldt, Karin , Ran, Caroline , Puschmann, Andreas , Hellberg, Clara , Clarke, Carl E , Morrison, Karen , Krainc, Dimitri , Burbulla, Lena F. , Krüger, Rejko , Gasser, Thomas , Sharma, Manu , Elbaz, Alexis , Deutschländer, Angela B., Puschmann, Andreas , Bardien, Soraya , Bobbili, Dheeraj R , Toft, Mathias , Ezquerra, Mario , Elbaz, Alexis , Grover, Sandeep , May, Patrick , Ferreira, Joaquim J , Zimprich, Alexander , Pastor, Pau , Koks, Sulev , Sugier, Pierre‐Emmanuel , Schulte, Claudia , Rogaeva, Ekaterina A. , Lang, Anthony E. , Taba, Pille , Brice, Alexis , Corvol, Jean‐Christophe , Mutez, Eugénie , Stefanis, Leonidas , Simitsi, Athina‐Maria , Valente, Enza Maria , Duga, Stefano , Zecchinelli, Anna , Gagliardi, Monica , Matsuo, Hirotaka , Nishioka, Kenya , Chung, Sun Ju , Pihlstrøm, Lasse , Guedes, Leonor Correia , Carr, Jonathan , Díez-Fairén, Mónica , Pedersen, Nancy L. , Belin, Andrea Carmine , Tan, Manuela , Farrer, Matthew J. , Domenighetti, Cloé

Mayo Clinic

Journal of Parkinson's Disease | October 9, 2021 | Volume: 12 | Issue: 1 | Pages: 267-282

10.3233/jpd-212851 | PMID 34633332 Get It

Background: Previous studies showed that lifestyle behaviors (cigarette smoking, alcohol, coffee) are inversely associated with Parkinson’s disease (PD). The prodromal phase of PD raises the possibility that these associations may be explained by reverse causation. Objective: To examine associations of lifestyle behaviors with PD using two-sample Mendelian randomisation (MR) and the potential for survival and incidence-prevalence biases. Methods: We used summary statistics from publicly available studies to estimate the association of genetic polymorphisms with lifestyle behaviors, and from Courage-PD (7,369 cases, 7,018 controls; European ancestry) to estimate the association of these variants with PD. We used the inverse-variance weighted method to compute odds ratios (ORIVW) of PD and 95%confidence intervals (CI). Significance was determined using a Bonferroni-corrected significance threshold (p = 0.017). Results: We found a significant inverse association between smoking initiation and PD (ORIVW per 1-SD increase in the prevalence of ever smoking = 0.74, 95%CI = 0.60–0.93, p = 0.009) without significant directional pleiotropy. Associations in participants ≤67 years old and cases with disease duration ≤7 years were of a similar size. No significant associations were observed for alcohol and coffee drinking. In reverse MR, genetic liability toward PD was not associated with smoking or coffee drinking but was positively associated with alcohol drinking. Conclusion: Our findings are in favor of an inverse association between smoking and PD that is not explained by reverse causation, confounding, and survival or incidence-prevalence biases. Genetic liability toward PD was positively associated with alcohol drinking. Conclusions on the association of alcohol and coffee drinking with PD are hampered by insufficient statistical power.
Survival in Young-Onset Metastatic Colorectal Cancer: Findings From Cancer and Leukemia Group B (Alliance)/SWOG 80405
Lipsyc-Sharf, Marla , Zhang, Sui , Ou, Fang‐Shu , McCleary, Nadine J. , Niedzwiecki, Donna , Chang, I-Wen, Lenz, Heinz‐Josef , Blanke, Charles D. , Piawah, Sorbarikor , Bainter, Tiffany M., Fuchs, Charles S. , Innocenti, Federico , Goldberg, Richard M. , Meyerhardt, Jeffrey A. , Ng, Kimmie , Van Loon, Katherine , Venook, Alan P , Nixon, Andrew B , Goldberg, Richard M , O'Reilly, Eileen M , Meyerhardt, Jeffrey A , Ng, Kimmie , Ou, Fang-Shu , Niedzwiecki, Donna , Ma, Chao , Loon, Katherine Van , Venook, Alan P. , Mayer, Robert J. , Nixon, Andrew B. , O’Reilly, Eileen M.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | October 8, 2021 | Volume: 114 | Issue: 3 | Pages: 427-435

10.1093/jnci/djab200 | PMID 34636852 Get It

Abstract Background The incidence of young-onset colorectal cancer (yoCRC) is increasing. It is unknown if there are survival differences between young and older patients with metastatic colorectal cancer (mCRC). Methods We studied the association of age with survival in 2326 mCRC patients enrolled in the Cancer and Leukemia Group B and SWOG 80405 trial, a multicenter, randomized trial of first-line chemotherapy plus biologics. The primary and secondary outcomes of this study were overall survival (OS) and progression-free survival (PFS), respectively, which were assessed by Kaplan-Meier method and compared among younger vs older patients with the log-rank test. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated based on Cox proportional hazards modeling, adjusting for known prognostic variables. All statistical tests were 2-sided. Results Of 2326 eligible subjects, 514 (22.1%) were younger than age 50 years at study entry (yoCRC cohort). The median age of yoCRC patients was 44.3 vs 62.5 years in patients aged 50 years and older. There was no statistically significant difference in OS between yoCRC vs older-onset patients (median = 27.07 vs 26.12 months; adjusted HR = 0.98, 95% CI = 0.88 to 1.10; P = .78). The median PFS was also similar in yoCRC vs older patients (10.87 vs 10.55 months) with an adjusted hazard ratio of 1.02 (95% CI = 0.92 to 1.13; P = .67). Patients younger than age 35 years had the shortest OS with median OS of 21.95 vs 26.12 months in older-onset patients with an adjusted hazard ratio of 1.08 (95% CI = 0.81 to 1.44; Ptrend = .93). Conclusion In this large study of mCRC patients, there were no statistically significant differences in survival between patients with yoCRC and CRC patients aged 50 years and older.
Novel Models of Genetic Education and Testing for Pancreatic Cancer Interception: Preliminary Results from the GENERATE Study
Furniss, C. Sloane , Yurgelun, Matthew B. , Constantinou, Pamela E., Lafferty, Catherine C., Talcove-Berko, Eliana R., Schwartz, Alison , Stopfer, Jill E. , Underhill‐Blazey, Meghan , Kenner, Barbara , Nelson, Scott H., Okumura, Sydney, Law, Sherman , Coffin, Tara B. , Rodriguez, Nicolette J. , Uno, Hajime , Ocean, Allyson J. , McAllister, Florencia , Lowy, Andrew M. , Lippman, Scott M. , Madlensky, Lisa , Petersen, Gloria M. , Uno, Hajime , Lowy, Andrew M , Klein, Alison P , Garber, J. E. , Syngal, Sapna , Ukaegbu, Chinedu I. , Nelson, Scott H., Zhou, Alicia Yiran , Klein, Alison P. , Garber, Judy E. , Goggins, Michael , Maitra, Anirban

Mayo Clinic

Cancer Prevention Research | October 8, 2021 | Volume: 14 | Issue: 11 | Pages: 1021-1032

10.1158/1940-6207.capr-20-0642 | PMID 34625409 Get It

Abstract Up to 10% of patients with pancreatic ductal adenocarcinoma (PDAC) carry underlying germline pathogenic variants in cancer susceptibility genes. The GENetic Education Risk Assessment and TEsting (GENERATE) study aimed to evaluate novel methods of genetic education and testing in relatives of patients with PDAC. Eligible individuals had a family history of PDAC and a relative with a germline pathogenic variant in APC, ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2, PMS2, STK11, or TP53 genes. Participants were recruited at six academic cancer centers and through social media campaigns and patient advocacy efforts. Enrollment occurred via the study website (https://GENERATEstudy.org) and all participation, including collecting a saliva sample for genetic testing, could be done from home. Participants were randomized to one of two remote methods that delivered genetic education about the risks of inherited PDAC and strategies for surveillance. The primary outcome of the study was uptake of genetic testing. From 5/8/2019 to 5/6/2020, 49 participants were randomized to each of the intervention arms. Overall, 90 of 98 (92%) of randomized participants completed genetic testing. The most frequently detected pathogenic variants included those in BRCA2 (N = 15, 17%), ATM (N = 11, 12%), and CDKN2A (N = 4, 4%). Participation in the study remained steady throughout the onset of the Coronavirus disease (COVID-19) pandemic. Preliminary data from the GENERATE study indicate success of remote alternatives to traditional cascade testing, with genetic testing rates over 90% and a high rate of identification of germline pathogenic variant carriers who would be ideal candidates for PDAC interception approaches. Prevention Relevance: Preliminary data from the GENERATE study indicate success of remote alternatives for pancreatic cancer genetic testing and education, with genetic testing uptake rates over 90% and a high rate of identification of germline pathogenic variant carriers who would be ideal candidates for pancreatic cancer interception.
Procainamide pharmacokinetics during extracorporeal membrane oxygenation
Vollmer, Nicholas , Wittwer, Erica D. , Rosenbaum, Andrew , Wieruszewski, Patrick M. , Vollmer, Nicholas J , Rosenbaum, Andrew N , Wieruszewski, Patrick M

Mayo Clinic

Perfusion | October 7, 2021 | Volume: 38 | Issue: 2 | Pages: 409-413

10.1177/02676591211050606 | PMID 34617854 Get It

Procainamide is a useful agent for management of ventricular arrhythmia, however its disposition and appropriate dosing during extracorporeal membrane oxygenation (ECMO) is unknown. We report experience with continuous procainamide infusion in a critically ill adult requiring venoarterial ECMO for incessant ventricular tachycardia. Pharmacokinetic analysis of procainamide and its metabolite, N-acetylprocainamide (NAPA), was performed using serum and urine specimens. Kidney function was preserved, and sequencing of the N-acetyltransferase 2 gene revealed the patient was a phenotypic slow acetylator. Procainamide volume of distribution and half-life were calculated and found to be similar to healthy individuals. However, despite elevated serum procainamide concentrations, NAPA concentrations remained far lower in the serum and urine. The magnitude of procainamide and NAPA discordance suggested alternative contributors to the deranged pharmacokinetic profile, and we hypothesized NAPA sequestration by the ECMO circuit. Ultimately, the patient received orthotopic cardiac transplantation and was discharged home in stable condition. Procainamide should be used cautiously during ECMO, with close therapeutic drug monitoring of serum procainamide and NAPA concentrations. The achievement of therapeutic NAPA concentrations while maintaining safe serum procainamide concentrations during ECMO support may be challenging.
A High-Sensitivity International Knee Documentation Committee Survey Index From the PROMIS System: The Next-Generation Patient-Reported Outcome for a Knee Injury Population
Robins, Richard J. , Sheean, Andrew J. , Dekker, Travis J. , Collaborative, MOTION, Bailey, James R. , Bharmal, Husain, Bradley, Matthew W. , Cameron, Kenneth L. , Burns, Travis C. , Freedman, Brett A. , Grenier, Eric, Haley, Chad A., Hurvitz, Andrew P. , Mauntel, Timothy C. , McDonald, Lucas S. , Nesti, Leon J. , Posner, Matthew, Provencher, Matthew T. , Roach, Christopher J., Slabaugh, Mark A. , Tucker, Christopher J. , Volk, William R., Dickens, Jonathan F. , Dickens, Jonathan F , Tenan, Matthew S. , Collaborative, MOTION, Galvin, Joseph W. , LeClere, Lance E. , Lee, Ian , Owens, Brett D. , Potter, Benjamin Kyle , Rhon, Daniel I. , Ryan, Paul M. , Schmitz, Matthew R.

Mayo Clinic

The American Journal of Sports Medicine | October 6, 2021 | Volume: 49 | Issue: 13 | Pages: 3561-3568

10.1177/03635465211041593 | PMID 34612705 Get It

Background: Patient-reported outcomes (PROs) measure progression and quality of care. While legacy PROs such as the International Knee Documentation Committee (IKDC) survey are well-validated, a lengthy PRO creates a time burden on patients, decreasing adherence. In recent years, PROs such as the Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Function and Pain Interference surveys were developed as computer adaptive tests, reducing time to completion. Previous studies have examined correlation between legacy PROs and PROMIS; however, no studies have developed effective prediction models utilizing PROMIS to create an IKDC index. While the IKDC is the standard knee PRO, computer adaptive PROs offer numerous practical advantages. Purpose: To develop a nonlinear predictive model utilizing PROMIS Physical Function and Pain Interference to estimate IKDC survey scores and examine algorithm sensitivity and validity. Study Design: Cohort study (diagnosis); Level of evidence, 3. Methods: The MOTION (Military Orthopaedics Tracking Injuries and Outcomes Network) database is a prospectively collected repository of PROs and intraoperative variables. Patients undergoing knee surgery completed the IKDC and PROMIS surveys at varying time points. Nonlinear multivariable predictive models using Gaussian and beta distributions were created to establish an IKDC index score, which was then validated using leave-one-out techniques and minimal clinically important difference analysis. Results: A total of 1011 patients completed the IKDC and PROMIS Physical Function and Pain Interference, providing 1618 complete observations. The algorithms for the Gaussian and beta distribution were validated to predict the IKDC (Pearson = 0.84-0.86; R 2 = 0.71-0.74; root mean square error = 9.3-10.0). Conclusion: The publicly available predictive models can approximate the IKDC score. The results can be used to compare PROMIS Physical Function and Pain Interference against historical IKDC scores by creating an IKDC index score. Serial use of the IKDC index allows for a lower minimal clinically important difference than the conventional IKDC. PROMIS can be substituted to reduce patient burden, increase completion rates, and produce orthopaedic-specific survey analogs.
Multiple sclerosis diagnosis: Knowledge gaps and opportunities for educational intervention in neurologists in the United States
Solomon, Andrew , Kaisey, Marwa , Krieger, Stephen, Chahin, Salim , Weinstein, Sarah M. , Weinstein, Sarah M , Naismith, Robert T. , Shinohara, Russell Taki , Weinshenker, Brian G.

Mayo Clinic

Multiple Sclerosis Journal | October 6, 2021 | Volume: 28 | Issue: 8 | Pages: 1248-1256

10.1177/13524585211048401 | PMID 34612110 Get It

Background: Few studies have addressed the results of educational efforts concerning proper use of McDonald criteria (MC) revisions outside multiple sclerosis (MS) subspecialty centers. Neurology residents and MS subspecialist neurologists demonstrated knowledge gaps for core elements of the MC in a recent prior study. Objective: To assess comprehension and application of MC core elements by non-MS specialist neurologists in the United States who routinely diagnose MS. Methods: Through a cross-sectional study design, a previously developed survey instrument was distributed online. Results: A total of 222 neurologists completed the study survey. Syndromes atypical for MS were frequently incorrectly considered “typical” MS presentations. Fourteen percent correctly identified definitions of both “periventricular” and “juxtacortical” lesions and 2% correctly applied these terms to 9/9 images. Twenty-four percent correctly identified all four central nervous system (CNS) regions for satisfaction of magnetic resonance imaging (MRI) dissemination in space. In two presented cases, 61% and 71% correctly identified dissemination in time (DIT) was not fulfilled, and 85% and 86% subsequently accepted nonspecific historical symptoms without objective evidence for DIT fulfillment. Conclusion: The high rate of knowledge deficiencies and application errors of core elements of the MC demonstrated by participants in this study raise pressing questions concerning adequacy of dissemination and educational efforts upon publication of revisions to MC.
Genome-Wide Association Study of Peripheral Artery Disease
Zuydam, Natalie R. van , Stiby, Alexander, Abdalla, Moustafa , Austin, Erin , McLachlan, Stela , Vlachopoulou, Efthymia, Ahlqvist, Emma , Liao, Chen Di , Sandholm, Niina , Robertson, Neil R., Rayner, Nigel W. , Lindholm, Eero , Sinisalo, Juha , Kallio, Milla , Weiss, Emily , Price, Jackie F. , Paterson, Andrew D. , Klein, Barbara E.K. , Palmer, Colin N.A. , Groop, Per‐Henrik , Groop, Leif , Morris, Andrew P. , Hopewell, Jemma C. , Colhoun, Helen M. , Grétarsdóttir, Sólveig , Þorsteinsdóttir, Unnur , Stefánsson, Kāri , Michael, Mark , Kanninen, Timo, Patrono, Carlo, Nuutila, Pirjo , McKeague, Paul, Steckel-Hamann, Birgit, Gan, Li‐Ming , Nogoceke, Everson, Jablonka, Bernd, Brosnan, Mary-Julia, van Zuydam, Natalie R , Ahlqvist, Emma , Di Liao, Chen , Sandholm, Niina , Forsblom, Carol , Rayner, N William , Lindholm, Eero , Sinisalo, Juha , Perola, Markus , Kallio, Milla , Weiss, Emily , Paterson, Andrew , Salomaa, Veikko , Palmer, Colin N A , McCarthy, Mark I , de Andrade, Mariza , Hopewell, Jemma C , Colhoun, Helen M , Kullo, Iftikhar J , Dahlström, Emma H. , Mahajan, Anubha , McCarthy, Mark I. , Andrade, Mariza de , Kullo, Iftikhar J. , Þorleifsson, Guðmar , Mark, Michael, Thorand, Barbara , Remuzzi, Giuseppe , Dunger, David B. , Shore, Angela C. , Smith, Ulf , Ylä-Herttuala, Seppo , Cobelli, Claudio , Bellazzi, Riccardo , Ferrannini, Ele , Patrono, Carlo, Tortoli, Piero

Mayo Clinic

Circulation: Genomic and Precision Medicine | October 4, 2021 | Volume: 14 | Issue: 5 | Pages: No page available

10.1161/circgen.119.002862 | PMID 34601942 Get It

Background: Peripheral artery disease (PAD) affects >200 million people worldwide and is associated with high mortality and morbidity. We sought to identify genomic variants associated with PAD overall and in the contexts of diabetes and smoking status. Methods: We identified genetic variants associated with PAD and then meta-analyzed with published summary statistics from the Million Veterans Program and UK Biobank to replicate their findings. Next, we ran stratified genome-wide association analysis in ever smokers, never smokers, individuals with diabetes, and individuals with no history of diabetes and corresponding interaction analyses, to identify variants that modify the risk of PAD by diabetic or smoking status. Results: We identified 5 genome-wide significant ( P association ≤5×10 −8 ) associations with PAD in 449 548 (N cases =12 086) individuals of European ancestry near LPA (lipoprotein [a]), CDKN2BAS1 (CDKN2B antisense RNA 1), SH2B3 (SH2B adaptor protein 3) - PTPN11 (protein tyrosine phosphatase non-receptor type 11), HDAC9 (histone deacetylase 9), and CHRNA3 (cholinergic receptor nicotinic alpha 3 subunit ) loci (which overlapped previously reported associations). Meta-analysis with variants previously associated with PAD showed that 18 of 19 published variants remained genome-wide significant. In individuals with diabetes, rs116405693 at the CCSER1 (coiled-coil serine rich protein 1 ) locus was associated with PAD (odds ratio [95% CI], 1.51 [1.32–1.74], P diabetes =2.5×10 −9 , P interactionwithdiabetes =5.3×10 −7 ). Furthermore, in smokers, rs12910984 at the CHRNA3 locus was associated with PAD (odds ratio [95% CI], 1.15 [1.11–1.19], P smokers =9.3×10 −10 , P interactionwithsmoking =3.9×10 −5 ). Conclusions: Our analyses confirm the published genetic associations with PAD and identify novel variants that may influence susceptibility to PAD in the context of diabetes or smoking status.
Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence
Slingluff, Craig L. , Lewis, Karl D. , Andtbacka, Robert Hans Ingemar, Hyngstrom, John , Milhem, Mohammed , Bowles, Tawnya L. , Hamid, Omid , Hernandez‐Aya, Leonel F. , Claveau, Joël, Jang, Sekwon, Philips, Prejesh, Holtan, Shernan G. , Shaheen, Montaser , Curti, Brendan D. , Schmidt, William, Butler, Marcus O. , Paramo, Juan, Lutzky, Jose , Padmanabhan, Arvinda, Thomas, Sajeve , Milton, Daniel T., Pecora, Andrew L. , Sato, Takami , Hsueh, Eddy C. , Badarinath, Suprith, Keech, John A., Kalmadi, Sujith, Kumar, Pallavi , Weber, Robert, Levine, Edward A. , Berger, Adam C. , Bar, Anna, Travers, Jeffrey B. , Mihalcioiu, Catalin , Gastman, Brian , Beitsch, Peter D. , Rapisuwon, Suthee , McCarron, Edward C. , Gupta, Vinay , Behl, Deepti , Blumenstein, Brent A. , Peterkin, Joanna, Curti, Brendan , Lutzky, Jose , Rapisuwon, Suthee , Milhem, Mohammed M , Butler, Marcus O , Levine, Edward A , Holtan, Shernan , Markovic, Svetomir N. , Paramo, Juan, Milton, Daniel, Beck, J. Thaddeus , Glaspy, John A.

Mayo Clinic

Journal for ImmunoTherapy of Cancer | October 1, 2021 | Volume: 9 | Issue: 10 | Pages: e003272

10.1136/jitc-2021-003272 | PMID 34599031 Get It

Background Most patients with advanced melanomas relapse after checkpoint blockade therapy. Thus, immunotherapies are needed that can be applied safely early, in the adjuvant setting. Seviprotimut-L is a vaccine containing human melanoma antigens, plus alum. To assess the efficacy of seviprotimut-L, the Melanoma Antigen Vaccine Immunotherapy Study (MAVIS) was initiated as a three-part multicenter, double-blind, placebo-controlled phase III trial. Results from part B1 are reported here. Methods Patients with AJCC V.7 stage IIB-III cutaneous melanoma after resection were randomized 2:1, with stage stratification (IIB/C, IIIA, IIIB/C), to seviprotimut-L 40 mcg or placebo. Recurrence-free survival (RFS) was the primary endpoint. For an hypothesized HR of 0.625, one-sided alpha of 0.10, and power 80%, target enrollment was 325 patients. Results For randomized patients (n=347), arms were well-balanced, and treatment-emergent adverse events were similar for seviprotimut-L and placebo. For the primary intent-to-treat endpoint of RFS, the estimated HR was 0.881 (95% CI: 0.629 to 1.233), with stratified logrank p=0.46. However, estimated HRs were not uniform over the stage randomized strata, with HRs (95% CIs) for stages IIB/IIC, IIIA, IIIB/IIIC of 0.67 (95% CI: 0.37 to 1.19), 0.72 (95% CI: 0.35 to 1.50), and 1.19 (95% CI: 0.72 to 1.97), respectively. In the stage IIB/IIC stratum, the effect on RFS was greatest for patients <60 years old (HR=0.324 (95% CI: 0.121 to 0.864)) and those with ulcerated primary melanomas (HR=0.493 (95% CI: 0.255 to 0.952)). Conclusions Seviprotimut-L is very well tolerated. Exploratory efficacy model estimation supports further study in stage IIB/IIC patients, especially younger patients and those with ulcerated melanomas. Trial registration number NCT01546571.